<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04223349</url>
  </required_header>
  <id_info>
    <org_study_id>CR108728</org_study_id>
    <secondary_id>70033093THR1004</secondary_id>
    <nct_id>NCT04223349</nct_id>
  </id_info>
  <brief_title>A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants</brief_title>
  <official_title>A Phase 1, Open-label Single-dose Crossover, and Double-blind Multiple-dose Parallel Group Study to Characterize the Pharmacokinetics, Safety and Tolerability, and Pharmacodynamics of JNJ-70033093 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the pharmacokinetic (PK) of multiple twice-daily&#xD;
      doses of JNJ-70033093 in healthy participants and to assess the effects of dosing time and&#xD;
      food on the PK of single-dose of JNJ-70033093 in healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 10, 2020</start_date>
  <completion_date type="Actual">April 8, 2020</completion_date>
  <primary_completion_date type="Actual">April 8, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Maximum Observed Analyte Concentration (Cmax) of JNJ-70033093</measure>
    <time_frame>Up to Day 9</time_frame>
    <description>Cmax is the maximum observed analyte concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Time to Reach the Maximum Observed Analyte Concentration (Tmax) of JNJ-70033093</measure>
    <time_frame>Up to Day 9</time_frame>
    <description>Tmax is the actual sampling time to reach the maximum observed analyte concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Area Under the Analyte Concentration-time Curve from Time Zero to 12 Hours (AUC[0-12h]) of JNJ-70033093</measure>
    <time_frame>12 hours postdose (Day 1)</time_frame>
    <description>AUC(0-12h) is the area under the time-concentration curve (AUC) from time 0 (dosing time) to 12 hours before steady state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Apparent Terminal Elimination Half-life (t[1/2]) of JNJ-70033093</measure>
    <time_frame>Up to Day 9</time_frame>
    <description>T(1/2) is the apparent terminal elimination half-life is the time measured for the analyte concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Maximum Observed Analyte Concentration (Cmax) of JNJ-70033093</measure>
    <time_frame>Up to Day 9</time_frame>
    <description>Cmax is the maximum observed analyte concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Area Under the Concentration-time Curve from Time Zero to the Last Measurable Concentration (AUC [0-last]) of JNJ-70033093</measure>
    <time_frame>Up to Day 9</time_frame>
    <description>AUC (0-last) is area under the analyte concentration-time curve (AUC) from time 0 to time of the last quantifiable (non-below quantification limit [non-BQL]) concentration, calculated by linear-linear trapezoidal summation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Area Under the Concentration-time Curve from Time Zero to Infinity (AUC [0-infinity]) of JNJ-70033093</measure>
    <time_frame>Up to Day 9</time_frame>
    <description>AUC (0-infinity) is the area under the analyte concentration-time curve (AUC) from time zero to infinite time, calculated as the sum of AUC (0-last) and C(last)/lambda(z); wherein AUC (0-last) is area under the plasma concentration-time curve from time zero to last measurable concentration, C(last) is the last observed measurable (non-BQL) analyte concentration; and lambda(z) is apparent terminal elimination rate constant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to 51 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product does not necessarily have a causal relationship with the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Vital Sign Abnormalities</measure>
    <time_frame>Up to 51 days</time_frame>
    <description>Number of participants with vital signs (including body temperature, resting [supine] pulse rate, and blood pressure) abnormalities will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Abnormal Electrocardiogram (ECG) Findings</measure>
    <time_frame>Up to 51 days</time_frame>
    <description>Number of participants with abnormal ECG findings will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Abnormal Laboratory Findings</measure>
    <time_frame>Up to 51 days</time_frame>
    <description>Number of participants with abnormal laboratory findings (that is, hematology, coagulation tests, clinical chemistry, urinalysis) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between JNJ-70033093 Plasma Concentrations and QTc After Multiple Doses of JNJ-70033093</measure>
    <time_frame>Up to Day 9</time_frame>
    <description>Relationship between JNJ-70033093 plasma concentrations and QTc in healthy participants receiving multiple doses of JNJ-70033093 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change from Baseline in Activated Partial Thromboplastin Time (aPTT)</measure>
    <time_frame>Baseline up to Day 9 (Part 1); Baseline up to Day 11 (Part 2)</time_frame>
    <description>aPTT measures the time to clot formation via the contact and common activation pathway. Blood will be collected for measurement of changes in aPTT clotting time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change from Baseline in Factor XI Clotting Activity</measure>
    <time_frame>Baseline up to Day 9 (Part 1); Baseline up to Day 11 (Part 2)</time_frame>
    <description>Percentage change from baseline in FXI clotting activity will be measured using a modified aPTT assay.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part 1: Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive JNJ-70033093 dose twice daily (BID) for 8 days followed by a placebo dose on Day 9 or placebo BID for 8 days followed by a placebo dose on Day 9.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive JNJ-70033093 dose BID for 8 days followed by a placebo dose on Day 9 or placebo BID for 8 days followed by a placebo dose on Day 9.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive JNJ-70033093 dose BID for 8 days followed by a JNJ-70033093 dose on Day 9 or placebo BID for 8 days followed by a placebo dose on Day 9.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Treatment D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive JNJ-70033093 dose BID for 8 days followed by a JNJ-70033093 dose on Day 9 or placebo BID for 8 days followed by a placebo dose on Day 9.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Treatment Sequence EFG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment E (JNJ-7003309 single dose in the morning in fasted condition) in treatment Period 1; followed by Treatment F (JNJ-7003309 single dose administered in the evening in fasted condition) in treatment Period 2; followed by Treatment G (JNJ-7003309 single dose administered in the evening in fasted condition) in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Treatment Sequence FGE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment F in treatment Period 1; followed by Treatment G in treatment Period 2; followed by Treatment E in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Treatment Sequence GEF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment G in treatment Period 1; followed by Treatment E in treatment Period 2; followed by Treatment F in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Treatment Sequence EGF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment E in treatment Period 1; followed by Treatment G in treatment Period 2; followed by Treatment F in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Treatment Sequence GFE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment G in treatment Period 1; followed by Treatment F in treatment Period 2; followed by Treatment E in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Treatment Sequence FEG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment F in treatment Period 1; followed by Treatment E in treatment Period 2; followed by Treatment G in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-70033093</intervention_name>
    <description>JNJ-70033093 capsules will be administered orally .</description>
    <arm_group_label>Part 1: Treatment A</arm_group_label>
    <arm_group_label>Part 1: Treatment B</arm_group_label>
    <arm_group_label>Part 1: Treatment C</arm_group_label>
    <arm_group_label>Part 1: Treatment D</arm_group_label>
    <arm_group_label>Part 2: Treatment Sequence EFG</arm_group_label>
    <arm_group_label>Part 2: Treatment Sequence EGF</arm_group_label>
    <arm_group_label>Part 2: Treatment Sequence FEG</arm_group_label>
    <arm_group_label>Part 2: Treatment Sequence FGE</arm_group_label>
    <arm_group_label>Part 2: Treatment Sequence GEF</arm_group_label>
    <arm_group_label>Part 2: Treatment Sequence GFE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo in capsule will be administered orally.</description>
    <arm_group_label>Part 1: Treatment A</arm_group_label>
    <arm_group_label>Part 1: Treatment B</arm_group_label>
    <arm_group_label>Part 1: Treatment C</arm_group_label>
    <arm_group_label>Part 1: Treatment D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy on the basis of medical history, physical examination, vital signs,&#xD;
             electrocardiogram (ECG), and laboratory test results, including serum chemistry, blood&#xD;
             coagulation, hematology, and urinalysis performed at screening. If there are&#xD;
             abnormalities, the investigator may decide that the abnormalities or deviations from&#xD;
             normal are not clinically significant. This determination must be recorded in the&#xD;
             participant's source documents and initialed by the investigator&#xD;
&#xD;
          -  If a woman, except for postmenopausal women, must have a negative highly sensitive&#xD;
             serum (beta human chorionic gonadotropin [beta-hCG]) at screening and urine (beta-hCG)&#xD;
             pregnancy test on Day -1 of treatment period&#xD;
&#xD;
          -  Contraceptive use by men or women should be consistent with local regulations&#xD;
             regarding the use of contraceptive methods for participant participating in clinical&#xD;
             studies&#xD;
&#xD;
          -  Body mass index (BMI; weight kilogram per meter square [kg/m^2]) between 18 and 30&#xD;
             kg/m^2 (inclusive), and body weight not less than 50 kilogram (kg)&#xD;
&#xD;
          -  After being supine for 10 minutes, systolic blood pressure between 90 and 140&#xD;
             millimeter of Mercury (mmHg), inclusive; and no higher than 90 mmHg diastolic blood&#xD;
             pressure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  If a woman, pregnant, breast-feeding or planning to become pregnant during the study&#xD;
&#xD;
          -  History of any known illness that, in the opinion of the investigator, might confound&#xD;
             the results of the study or pose an additional risk in administering study drug to the&#xD;
             participant or that could prevent, limit or confound the protocol specified&#xD;
             assessments. This may include but is not limited to any known bleeding or clotting&#xD;
             disorder, a history of arterial or venous thrombosis, liver or renal dysfunction,&#xD;
             significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic,&#xD;
             hematologic, rheumatologic, psychiatric, neoplastic abnormalities, metabolic&#xD;
             disturbances, or poor venous access&#xD;
&#xD;
          -  Participants with current hepatitis B infection (confirmed by hepatitis B surface&#xD;
             antigen [HBsAg]), or hepatitis C infection (confirmed by hepatitis C virus [HCV]&#xD;
             antibody), or human immunodeficiency virus type-1 (HIV-1) or HIV-2 infection at study&#xD;
             screening&#xD;
&#xD;
          -  History of, or a reason to believe a participant has a history of, drug or alcohol&#xD;
             abuse according to Diagnostic and Statistical Manual of Mental Disorders (5th edition)&#xD;
             (DSM V) criteria within the past 1 year, which in the investigator's opinion would&#xD;
             compromise participant safety and/or compliance with the study procedures&#xD;
&#xD;
          -  History of any clinically significant drug or food allergies (such as anaphylaxis or&#xD;
             hepatotoxicity) and known allergy to the study drugs or any of the excipients of the&#xD;
             formulation. History of allergy to or unwillingness to consume any component of the&#xD;
             high-fat breakfast menu to be provided in this study&#xD;
&#xD;
          -  Clinically significant abnormal values for hematology, coagulation, clinical chemistry&#xD;
             or urinalysis at Screening or on Day -1 prior to the first dosing as determined by the&#xD;
             investigator or appropriate designee. Any of the following laboratory results outside&#xD;
             of the ranges specified below at screening or Day -1 prior to first dosing, confirmed&#xD;
             by repeat: Hemoglobin or hematocrit &lt; lower limit of normal; Platelet count &lt; lower&#xD;
             limit of normal; activated partial thromboplastin time (aPTT), or prothrombin time&#xD;
             (PT) greater than (&gt;) 1.2 × upper limit of normal (ULN)&#xD;
&#xD;
          -  Any of the following on 12-lead ECG and assessment of QT interval prior to study&#xD;
             treatment administration, confirmed by repeat at screening and Day -1 of treatment&#xD;
             period: Heart rate &gt;100 beats per minute (bpm); PR &gt;= 210 milli second (ms); QRS &gt;=120&#xD;
             ms; QTcF &gt;= 450 ms for male and &gt;= 470 ms for female&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 8, 2020</study_first_submitted>
  <study_first_submitted_qc>January 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2020</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

